Clinical Trial

Artificial Intelligence-Based Assessment of Endosseous Lesions

Study acronym: AIpreop
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Despite these advances, CBCT interpretation remains largely qualitative and dependent on the clinician's experience. Conventional evaluation is based on two-dimensional slices and linear measurements, which may underestimate lesion complexity and spatial distribution. Recent developments in Artificial Intelligence in Medicine have introduced automated image segmentation tools capable of identifying lesion boundaries and calculating volumetric data. These technologies allow a transition from subjective assessment to objective, reproducible quantification. The potential clinical advantages include: * Objective measurement of lesion size (volume in mm³) * Improved surgical planning * Enhanced prediction of anatomical involvement * Reduction of diagnostic errors * Standardization of follow-up and outcome assessment Therefore, the aim of the present study was to evaluate the clinical impact of AI-based segmentation and volumetric analysis of endosseous lesions compared to conventional CBCT interpretation.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-16
notable Primary completion pushed: 2026-04-01 -> 2026-05-01 2026-04-16
Trial Details
NCT Number NCT07505485
Lead Sponsor University of Bari Aldo Moro
Conditions Maxillary Cyst, Mandibular Cyst
Enrollment 10 participants
Start Date 2026-04-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-15